Advertisement

Antiandrogens: Clinical Aspects

  • J. Hammerstein
Chapter

Abstract

For a long time, the only means for combatting hirsutism were ablative surgery, the mechanical removal of body hair such as through shaving, plucking, waxing, chemical depilation and electrolysis, or simply bleaching. When glucocorticoids became available in the early 1950s, it was hoped that adrenal hirsutism and virilism could be treated by the suppressive action of these hormonal compounds upon adrenal androgen hypersecretion via a reduction in the release of pituitary ACTH. In fact, this was shown by Wilkins et al. (1950) to be true in the case of congenital adrenal hyperplasia (originally, congenital, adrenogenital syndrome). Since that time the use of glucocorticoids has become the method of choice for this type of inborn enzymatic disturbance.

Keywords

Congenital Adrenal Hyperplasia Cyproterone Acetate Androgenetic Alopecia Sebum Production Hirsute Woman 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abshagen U, Besenfelder R, Endele R, Koch K, Neubert B (1979) Kinetics of canrenone after single and multiple doses of spironolactone. Eur J Clin Pharmacol 16:255CrossRefGoogle Scholar
  2. Abraham GE, Maroulis GB, Boyers SP, Buster JE, Magyar DM, Eisner CW (1981) Dexamethasone suppression test in the management of hyperandrogenized patients. Obstet Gynecol 57:158PubMedGoogle Scholar
  3. Abrahamsson L, Hackl H, Lindstrom B (1983) Einflüsse der Antiandrogen-Behandlung mit Cyproteroneazetate (CA) auf den Sexualtonus virilisierter Frauen. Wien Klin Wochenschr 95:49Google Scholar
  4. Abrahamsson L, Hackl H, Lindstrom B, Sogn J (1981) Langzeitbehandlung virilisierter Frauenmit Cyproteronazetat (CA). Wien Klin Wochenschr 93:552Google Scholar
  5. Abramovici Y, Guillet F, Matte R, Chaieb L, Belanger R (1983) La spironolactone dans l’hirsutisme idiopathique, evaluations clinique et biologique du traitment. Ann Endocrinol (Paris) 44:393Google Scholar
  6. Anderson JA (1978) An assessment of (1) cyproterone acetate and (2) ethinyl oestradiol and lynoestrenol (Minilyn) in the treatment of idiopathic hirsutism. Br J Dermatol 99:545PubMedCrossRefGoogle Scholar
  7. Appelt H, Strauss B (1984) Effects of antiandrogen treatment on the sexuality of women with hyperandrogenism. Psychother Psychosom 42:177PubMedCrossRefGoogle Scholar
  8. Aram H (1987) Treatment of female androgenetic alopecia with Cimetidine. Int J Dermatol 26:128PubMedCrossRefGoogle Scholar
  9. Aydinlik S, Lachnit-Fixson U (1977) Diane — eine Gestagen-Östrogen-Kombination mit Antian-drogenwirkung. Med Monatsschr Pharm 31:425Google Scholar
  10. Aydinlik S, Lachnit-Fixson U, Lehnert J (1986) Östrogenreduzierter Ovulationshemmer zur Aknetherapie. Doppelblindstudie zum Vergleich von Diane-35 gegen Diane. Fortschr Med 104:547PubMedGoogle Scholar
  11. Baranowska B, Stopinska-Gluszak U, Niewiadomska A, Rozbicka G (1983) Application of cyproterone acetate (Androcur) for treatment of idiopathic hirsutism and hirsutism associated with polycystic ovary syndrome. Endokrynol Pol 34:227Google Scholar
  12. Bardin CW, Lipsett MB (1967) Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J Clin Invest 46:891–897Google Scholar
  13. Barnes EW, Irvine WJ, Hunter WM, Ismail AAA (1975) Cyproterone acetate: a study involving two volunteers with idiopathic hirsutism. Clin Endocrinol 4:65CrossRefGoogle Scholar
  14. Baxendale PM, Jacobs HS, James VHT (1982) Salivary testosterone: relationship to unbound plasma testosterone in normal and hyperandrogenic women. Clin Endocr 16:595PubMedCrossRefGoogle Scholar
  15. Becker H, Düsterberg B, Klosterhalfen H (1980) Bioverfügbarkeit von Cyproteronacetat nach oraler und intramuskulärer Applikation bei Männern. Urol Int 35:381PubMedCrossRefGoogle Scholar
  16. Bellmann O, Bröschen-Zywietz C, Fichte K (1978) Serumkonzentrationen von Prolaktin, Wachstumshormon und Alpha-Fetoprotein bei Langzeiteinnahme eines Cyproteronehaltigen Kontrazeptivums. Geburtshilfe Frauenheilkd 38:549Google Scholar
  17. Bettendorf G (1968) Cassano C, Finkelstein M, Klopper A (eds) Research on steroids, vol 3. North Holland, Amsterdam, p 267Google Scholar
  18. Biffignandi P, Massucchetti C, Molinatti GM (1984) Female hirsutism: pathophysiological considerations and therapeutic implications. Endocr Rev 5:498PubMedCrossRefGoogle Scholar
  19. Boisselle A, Tremblay RR (1979) New therapeutic approach to the hirsute patient. Fertil Steril 32:276PubMedGoogle Scholar
  20. Braendle W, Boess H, Breckwoldt M, Leven C, Bettendorf G (1974) Wirkung und Nebenwirkung der Cyproteronacetatbehandlung. Arch Gynecol 216:335Google Scholar
  21. Breckwoldt M, Trolp R, Braendle W, Roll H, Rachel F (1978) Anti-androgen oral contraceptives. In: Haspels AA, Kay CR (eds) International symposium on hormonal contraception. International congress series 411. Excerpta Medica, Amsterdam, p 81Google Scholar
  22. Burgess CA, Edwards CRW (1978) Hirsutography. Br J Photography 8:770Google Scholar
  23. Burton JL, Johnson C, Libman L, Shuster S (1972) Skin virilism in women with hirsutism. J Endocrinol 53:349PubMedCrossRefGoogle Scholar
  24. Bye P (1986) Comments on “conception during ‘Diane’ therapy — a successful outcome” (letter). Br J Dermatol 114:516PubMedCrossRefGoogle Scholar
  25. Caminos-Torres R, Ma L, Snyder PJ (1977) Gynecomastia and semen abnormalities induced by spironolactone in normal men. J Clin Endocrinol Metab 45:255PubMedCrossRefGoogle Scholar
  26. Caplan RM (1967) Gynecomastia from a non-estrogenic anti-androgen. J Clin Endocrinol 27:1348CrossRefGoogle Scholar
  27. Carol W, Kluge K, Hempel E, Klinger G (1979) Erfahrungen mit dem Antiandrogen Cyproteronazetat bei der Behandlung des Hirsutismus. Zentralbl Gynäkol 101:497PubMedGoogle Scholar
  28. Caron P, Denis M, Bazex J, Leuvet JP (1983) Cimetidine, new acne treatment in women? Presse Med 12:1295Google Scholar
  29. Carr BR (1986) The effect of Spironolactone on aromatase activity. Fertil Steril 45:655PubMedGoogle Scholar
  30. Casey JH, Moxham A, Nabarro JDN (1964) Seasonal variation of hair-growth and response to oestrogen administration. Lancet 1:58Google Scholar
  31. Casey JH, Burger HG, Kent JR, Kellie AE, Moxham A, Nabarro JDN (1966) Treatment of hirsutism by adrenal and ovarian suppression. J Clin Endocrinol 26:1370CrossRefGoogle Scholar
  32. Cermak T, Fanta D, Schneider W (1981) Behandlung des Hirsutismus mit Cyproteronacetat. Z Hautkr 56:147PubMedGoogle Scholar
  33. Chapman MG, Jeffcoate S, Dewhurst J (1982 a) Reduced dose of oestrogen in combination with cyproterone acetate in the treatment of hirsutism. J Obstet Gynecol 3:62CrossRefGoogle Scholar
  34. Chapman MG, Jeffcoate SL, Dewhurst CJ (1982 b) Effect of cyproterone acetate-ethinyl oestradiol treatment on adrenal function in hirsute women. Clin Endocrinol (Oxf) 17:577CrossRefGoogle Scholar
  35. Chapman MG, Dowsett M, Dewhurst CJ, Jeffcoate SL (1985) Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism. Br J Obstet Gynecol 92:983CrossRefGoogle Scholar
  36. Chapman MG, Katz M, Hague W, Jeffcoate SL, Dewhurst CJ (1986) Spironolactone in the treatment of hirsutism. Acta Obstet Gynecol Scand 65:349PubMedCrossRefGoogle Scholar
  37. Chilvers E, Rudge P (1986) Cerebral venous thrombosis and subarachnoid haemorrhage in users of oral contraceptives. Br Med J 292:514CrossRefGoogle Scholar
  38. Cohen J (1984) Contraception et hyperandrogenie. Point de vue du gynecologue. Contraception Fertil Sex (Suppl) 12:133Google Scholar
  39. Corenblum B, Rosengarten A, Taylor PJ (1986) Evaluation de femmes hirsutes par la testosterone salivaire et leur traitement par la spironolactone. Contracept Fertil Sex 14:163Google Scholar
  40. Cremoncini C, Vignati E, Libroia A (1976) Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinyl-estradiol. Acta Eur Fertil 7:299PubMedGoogle Scholar
  41. Cullberg G, Hamberger L, Mattsson L-A, Mobacken H, Samsioe G (1985) Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrom. Acta Obstet Gynecol Scand 64:195PubMedCrossRefGoogle Scholar
  42. Cumming DC, Yang JC, Rebar RW, Yen SSC (1982) Treatment of hirsutism with spironolactone. J Am Med Assoc 247:1295CrossRefGoogle Scholar
  43. Cunliffe WJ, Shuster S, Cassels AJ (1969) The effect of topical cyproterone acetate on sebum secretion in patients with acne. Br J Dermatol 81:200PubMedCrossRefGoogle Scholar
  44. Cupceancu B, Hammerstein J (1969) Behandlung des Hirsutismus mit Corticoiden, Ovulationshemmern und Antiandrogenen. Geburtshilfe Frauenhkd 29:499Google Scholar
  45. Dalla Pria S, Greenblatt RB, Mahesh VB (1969) Antiandrogen in acne and idiopathic hirsutism. J Invest Dermatol 52:348PubMedGoogle Scholar
  46. Daniel S (1985) Die Pharmakokinetic von Cyproteronacetat unter der hochdosierten Standardtherapie bei androgenisierten Frauen. Thesis, Freie Universität BerlinGoogle Scholar
  47. Dawber RPR, Sonnex T, Ralfs I (1982) Oral anti-androgen treatment of common baldness in women. Br J Dermatol 107 (Suppl 22):20Google Scholar
  48. De Oliveira RFC (1976) A new treatment for hirsutism. Ann Intern Med 83:817Google Scholar
  49. Dewhurst CJ, Underhill RB, Goldman S, Mansfield M (1977) The treatment of hirsutism with cyproterone acetate (an anti-androgen). Br J Obstet Gynaecol 84:119PubMedCrossRefGoogle Scholar
  50. Dorrington-Ward P, McCartney ACE, Holland S, Scully J, Carter G, Alaghband-Zadeh J, Wise P (1985) The effect of spironolactone on hirsutism and female androgen metabolism. Clin Endocrinol (Oxf) 23:161CrossRefGoogle Scholar
  51. Droste-Vehn M (1990) 15β-Hydroxy-CPA und unverändertes CPA im Blut von Frauen unter umgekehrter Seynenztherapie mit CDA und EE. Thesis, Freie Universität, Berlin (in preparation)Google Scholar
  52. Ebling FJ, Thomas AK, Cooke ID, Randall VA, Skinner J, Dawood M (1977) Effect of cyproterone acetate on hair growth, sebaceous secretion and endocrine parameters in a hirsute subject. Br J Dermatol 97:371PubMedCrossRefGoogle Scholar
  53. Ebling FJG (1984) Hormones and hair: an update. J Appl Cosmetol 2:7Google Scholar
  54. Eil C, Edelson SK (1984) The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J Clin Endocrinol Metab 59:51PubMedCrossRefGoogle Scholar
  55. Evans DJ, Burke CW (1986) Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome. J R Soc Med 79:451PubMedGoogle Scholar
  56. Evron S, Shapiro G, Diamant YZ (1981) Induction of ovulation with spironolactone (aldactone) in anovulatory oligomenorrheic and hyperandrogenie women. Fertil Steril 36:468PubMedGoogle Scholar
  57. Falsetti L, Dordoni D, Gastaldi C, Gastaldi A (1986) A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary snydrome. Acta Eur Fertil 17:19PubMedGoogle Scholar
  58. Ferriman D, Gallway JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol 21:1440CrossRefGoogle Scholar
  59. Fixson U (1963) Vorläufige Mitteilung über ein neues oral wirksames Gestagen (SH 714). Geburtshilfe Frauenhkd 23:371Google Scholar
  60. Floersheim Y, Keller PJ (1976) Hormonale Behandlung des Hirsutismus. Schweiz Med Wochenschr 106:573PubMedGoogle Scholar
  61. Forbes AP (1965) Hypertrichosis. N Engl J Med 273:646CrossRefGoogle Scholar
  62. Fräser IS, Shearman RP, Allen JK, McCarron G (1983) Cyproterone acetate and the treatment of hirsutism. Aust NZJ Obstet Gynaecol 23:93CrossRefGoogle Scholar
  63. Frey H, Aakvaag A (1981) The treatment of essential hirsutism in women with cyproterone acetate and ethinyl estradiol. Clinical and endocrine effects in 10 cases. Acta Obstet Gynecol Scand 60:295PubMedCrossRefGoogle Scholar
  64. Frith RG, Phillipou G (1985) 15-Hydroxycyproterone acetate and cyproterone acetate levels in plasma and urine. J Chromatogr 338:179Google Scholar
  65. Frölich M, Lachinsky N, Mollenaar AJ (1977) The influence of combined cyproterone acetate-ethinyl oestradiol therapy in serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women. Acta Endocrinol (Copenh) 84:333Google Scholar
  66. Frölich M, Vader HL, Walma ST, De Rooy HA (1980) The influence of long-term treatment with cyproterone acetate or a cyproterone acetate-ethinyl oestradiol combination on androgen levels in blood of hirsute women. J Steroid Biochem 12:499PubMedCrossRefGoogle Scholar
  67. Garner PR, Poznanski N (1984) Treatment of severe hirsutism resulting from hyperandrogenism with the reverse sequential cyproterone acetate regimen. J Reprod Med 29:232PubMedGoogle Scholar
  68. Gerhards E, Gutsche H, Rieman J (1973) Biodynamik von l,2a-Methylen-6-chlor-pregna-4,6- dien-17a-acetoxy-3,20-dion (Cyproteron-acetat) nach oraler Verabreichung beim Menschen. Arzneimittelforschung 23:1550PubMedGoogle Scholar
  69. Girard J, Baumann JB (1975) Secondary adrenal insufficiency due to cyproterone acetate. Pediatr Res 9:669Google Scholar
  70. Girard J, Baumann JB, Bühler U, Zuppinger K, Haas HG, Staub JJ, Wyss HI (1978) Cyproteronacetate and ACTH adrenal function. J Clin Endocrinol Metab 47:581PubMedCrossRefGoogle Scholar
  71. Giusti M, Parazzi F, Reitano A, Bolognese F, Giordano G (1977) Longitudinal study of the behaviour of certain hormonal parameters in women undergoing treatment with cyproterone acetate. Acta Eur Fertil 8:211PubMedGoogle Scholar
  72. Göbel P (1968) Nebennierenrinde und Hirsutismus der Frau. Therapiewoche 18:729Google Scholar
  73. Goodfellow A, Alaghband-Zadeh J, Carter G, Cream JJ, Holland S, Scully J, Wise P (1984) Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 111:209PubMedCrossRefGoogle Scholar
  74. Gräf K-J, Brotherton J, Neumann F (1974) Clinical uses of antiandrogens. In: Voss HE, Oertel G (eds) Androgens and antiandrogens. Springer, Berlin Heidelberg New York, p 485 (Handbook of experimental pharmacology, vol 35/2)Google Scholar
  75. Gräf K-J, Schmidt-Gollwitzer M, Koch UJ, Lorenz F, Hammerstein J (1978) Hyperprolacti- naemia induced by cyproterone acetate in human subjects. Acta Endocrinol 87 (Suppl 215):96Google Scholar
  76. Grandesso R, Spandri R, Gangemi M, Nardelli GB, Ambrosio GB, Conte G, De Salvia D, Meneghetti G (1984) Hormonal changes and hair growth during treatment of hirsutism with Cimetidine. Clin Exp Obstet Gynecol 11:105PubMedGoogle Scholar
  77. Greenblatt RB (1967) Progestational agents in clinical practice. Mecical Science 18:37Google Scholar
  78. Greenblatt RB, Gambreil RD (1985) Epilogue. In: Greenblatt RB, Mahesh VB, Gambrell RD (eds) Unwanted hairits cause and treatment. Parthenon, Carnforth, p 178Google Scholar
  79. Grund E, Schmidt-Eimendorff H (1975) Behandlung von Virilisierungserscheinungen. Med Welt 26:2180PubMedGoogle Scholar
  80. Hague WM, Munro DS, Sawers RS, Duncan SLB, Honour JW (1982) Long-term effects of cyproterone acetate on the pituitary adrenal axis in adult women. Br J Obstet Gynaecol 89:981PubMedCrossRefGoogle Scholar
  81. Hammerstein J (1973) Antiandrogene. Arch Gynecol 214:243Google Scholar
  82. Hammerstein J (1980) Possible methods of endocrine therapy and Round-Table discussion. In: Hammerstein J, Lachnit-Fixson U, Neumann F, Plewig G (eds) Androgenization in women. Excerpta Medica, Amsterdam, p 221, p 278Google Scholar
  83. Hammerstein J, Cupceancu B (1969) Behandlung des Hirsutismus mit Cyproteronacetat. Dtsch Med Wochenschr 94:829 English Translation: The treatment of hirsutism with cyproterone acetate. German Medical Monthly 14:599PubMedCrossRefGoogle Scholar
  84. Hammerstein J, Meckies J, Leo-Roßberg I, Moltz L, Zielske F (1975) Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem 6:827PubMedCrossRefGoogle Scholar
  85. Hammerstein J, Moltz L, Schwartz U (1983) Antiandrogens in the treatment of acne and hirsutism. J Steroid Biochem 19:591PubMedCrossRefGoogle Scholar
  86. Hecker A, Hasan SH, Neumann F (1978) Effect of spironolactone on the sexual differentiation of rat fetuses. Acta Endocrinol (Copenh) 87 (Suppl 215):32Google Scholar
  87. Hefter EL, Miller JL, Rose LI (1988) Side effects of spironolactone in the hirsute women. J Clin Endocrinol Metab 66:208CrossRefGoogle Scholar
  88. Hertz R, Tullner WW (1958) Progestational activity of certain steroid-17 spironolactones. Proc Soc Exp Biol Med 99:451PubMedGoogle Scholar
  89. Holdaway IM, Croxson MS, Evans MC, France J, Sheehan A, Wilson T, Ibbertson HK (1983) Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism. Acta Endocrinol (Copenh) 104:222Google Scholar
  90. Holdaway IM, Fraser A, Sheehan A, Sheehan A., Croxson MS, France JT, Ibbertson HK (1985 a) Objective assessment of treatment response in hirsutism. Horm Res 22:253PubMedCrossRefGoogle Scholar
  91. Holdaway IM, Croxson MS, Ibbertson HK, Sheehan A, Knox B, France J (1985 b) Cyproterone acetate as initial treatment and maintenance therapy for hirsutism. Acta Endocrinol (Copenh) 109:522Google Scholar
  92. Houdent C, Kuhn JM, Balacheff O et al. (1983) Acetate de cyproterone. 15 cas d’hirsutisme traités un ans. Ann Endocrinol 44:397Google Scholar
  93. Hughes BR, Cunliffe WJ (1988) Tolerance of spironolactone. Brig J Dermatol 118:687CrossRefGoogle Scholar
  94. Hümpel M, Wendt H, Schulze PE, Dogs G, Weiss C, Speck U (1977 a) Bioavailability and pharmacokinetics of cyproterone acetate after oral administration of 2.0 mg cyproterone acetate in combination with 50 [ig etinylestradiol to 6 young women. Contraception 15:579PubMedCrossRefGoogle Scholar
  95. Hümpel M, Wendt H, Dogs G, Weiss C, Rietz S, Speck U (1977 b) Intraindividual comparison of pharmacokinetic parameters of d-norgestrel, lynestrenol and cyproterone acetate in 6 women. Contraception 16:199CrossRefGoogle Scholar
  96. Hümpel M, Dogs G, Wendt H, Speck U (1978) Plasmaspiegel und Pharmakokinetik von Cyproteronacetat nach oraler Applikation als 50-mg-Tablette bei 5 Männern. Arzneimittelforschung 28:319PubMedGoogle Scholar
  97. Inaudi P, D’Ambrogio G, Massafra C, Facchini V, Genazzani AR (1982) Impaired pregnenolone secretion after combined cyproterone acetate and ethynyl estradiol therapy in hirsute patients. Gynecol Obstet Invest 14:106PubMedCrossRefGoogle Scholar
  98. Ismail AAA, Davidson DW, Souka AR, Barnes EW, Irvine WJ, Kilimnik H, Vanderbeeken Y (1974) The evaluation of the role of androgens in hirsutism and the use of a new antiandrogen “cyproterone acetate” for therapy. J Clin Endocrinol Metab 39:81PubMedCrossRefGoogle Scholar
  99. Jaffiol C, Robin M, Boyer MC, Orsetti A (1979) Etude des hormones gonadotropes, de la prolamine et de l’hirsutisme par l’acetate de cyproterone. Rev Fr Endocrinol Clin Nutr Metab 20:456Google Scholar
  100. Jeffcoate WJ, Edwards CRW, Rees LH, Besser GM (1976) Cyproterone acetate. Lancet 11:1140CrossRefGoogle Scholar
  101. Jentsch D, Schulz V, Wendt H (1976) Pharmakokinetik von Cyproteronacetat bei gesunden Probanden nach intramuskulärer und oraler Applikation. Arzneimittelforschung 26:914PubMedGoogle Scholar
  102. Jones KR, Katz M, Keyzer C, Gordon W (1981) Effect of cyproterone acetate on rate of hair growth in hirsute females. Br J Dermatol 105:685PubMedCrossRefGoogle Scholar
  103. Jones H, Simpson NB, Blanc D, Forster RA, Cunliffe WJ (1980) Lack of effect of Cimetidine in acne. Lancet 2:1201PubMedCrossRefGoogle Scholar
  104. Jost B, Meiers HG, Schmidt-Eimendorff H, Pfaffenrath V (1974) Trichometrische Quantifizierung und Verlaufsbeurteilung des Hirsutismus. Dtsch Med Wochenschr 99:2395PubMedCrossRefGoogle Scholar
  105. Kaiser E, Schmidt-Elmendorff H, Zimmermann H, Solbach HG (1968) Harnund Plasmasteroide unter Antiandrogen (SH 80881) — Behandlung bei Frauen mit Hirsutismus. In: Klein E (ed) Das Testosteron — Die Struma. 13. Symposium der deutschen Gesellschaft für Endokrinologie. Springer, Berlin Heidelberg New York, p 109Google Scholar
  106. Karim A, Zagarella J, Hutseil TC, Dooley Y (1976) Spironolactone III. Canrenone. Maximum and minimum steady-state plasma levels. Clin Pharmacol Ther 19:177PubMedGoogle Scholar
  107. Keller FJ (1980) Round-Table discussion. In: Hammerstein J, Lachnit-Fixson U, Neumann F, Plewig G (eds) Androgenization in women. Excerpta Medica, Amsterdam, p 284Google Scholar
  108. Koch UJ, Lorenz F, Danehl K, Ericsson R, Hasan SH, Keyserlingk von D, Lübke K, Mehring M, Römmler A, Schwartz U, Hammerstein J (1976) Continuous oral low-dosage cyprogerone acetate for fertility regulation in the male? Contraception 14:117PubMedCrossRefGoogle Scholar
  109. Kolb KH, Röpke H (1968) Zur Pharmakokinetik von Cyproteronacetat. Eine vergleichende Studie bei Mensch und Pavian. Int J Clin Pharmacol 1:184Google Scholar
  110. Kuttenn F, Rigaud C, Wright F, Mauvais-Jarvis P (1980) Treatment of hirsutismus by oral cyproterone acetate and percutaneous estradiol. J Clin Endocrinol Metab 51:1107PubMedCrossRefGoogle Scholar
  111. Lachinsky N, Velde JN, Wildschut J (1976) Behandeling van hirsutisme met Cyproteronacetat. Ned Tijdschr Geneeskd 120:184PubMedGoogle Scholar
  112. Lachnit-Fixson U (1979) The development and evaluation of an ovulation inhibitor (Diane) containing an antiandrogen. Acta Obstet Gynecol Scand [Suppl] 88:33CrossRefGoogle Scholar
  113. Lachnit-Fixson U, Kaufmann J (1977) Zur Beeinflussung von Androgenisierungserscheinungen — Doppelblindstudie eines Cyproteronacetat-haltigen Präparates (SHB 209 AB) gegen Neogynon. Med Klin 72:1922PubMedGoogle Scholar
  114. Larsson-Cohn U, Fahraeus L, Schenck H von, Wallentin L (1986) Effects on the lipoprotein metabolism of an antiandrogen-estrogen oral contraceptive drug. Acta Obstet Gynecol Scand 65:125PubMedCrossRefGoogle Scholar
  115. Lebeau M, Vokaer R (1972) Traitement de l’hirsutisme et de l’acné. Leur thérapeutique séquentielle inversée anti-androgène/oestrogène. J Gynecol Obstet Biol Reprod (Paris) 1:715Google Scholar
  116. Leo-Roßberg I, Laur S, Zielske F, Hammerstein J (1971) Reverse sequential therapy of hirsutism using cyproterone acetate. I. Further clinical observations. Acta Endocrinol (Copenh) 66 (Suppl) 152:14Google Scholar
  117. Levy J, Burshell A, Marbach M, Ayllalo L, Glick JM (1980) Interaction of spironolactone with oestradiol receptors in cytosol. J Endocrinol 84:371PubMedCrossRefGoogle Scholar
  118. Lobo RA, Shoupe D, Serafini P, Brinton D, Horton R (1985) The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 43:200PubMedGoogle Scholar
  119. Lorenzo EM (1970) Familial study of hirsutism. J Clin Endocrinol Metab 31:556CrossRefGoogle Scholar
  120. Loriaux DL, Menard A, Taylor A, Pita JC, Santen R (1976) Spironolactone and endocrine dysfunction. Ann Intern Med 85:630Google Scholar
  121. Lundberg U, Hansson U, Eneroth P, Frankenhäuser M, Hagenfeldt K (1984) Anti-androgen treatment of hirsute women: a study on stress responses. J Psychosom Obstet Gynecol 3:79CrossRefGoogle Scholar
  122. Lunell NO, Zador G, Carlstroem K, Eneroth P, Patek E, Wagner J (1982) The effect of cyproterone acetate on pituitary-ovarian function and clinical symptoms in hirsute women. Acta Endocrinol (Copenh) 100:91Google Scholar
  123. Lux E, Gimes R, Csomor S, Rusz E (1982) Die Persönlichkeitsund Sozialbedeutung des Hirsutismus. Zentralbl Gynäkol 104(17):1100PubMedGoogle Scholar
  124. Lyons F, Cook J, Shuster S (1979) Inhibition of sebum excretion by an H2-blocker. Lancet 1:1376PubMedCrossRefGoogle Scholar
  125. Madert K-K (1980) Psychosomatische Aspekte des nichtsymptomatischen Hirsutismus. Geburtshilfe Frauenheilkd 40:648PubMedCrossRefGoogle Scholar
  126. Maggiolo J (1964) Medikamentöse Behandlung des Hirsutismus. Med Klin 59:1318PubMedGoogle Scholar
  127. Mahesh VB, Zarate A, Roper BK, Greenblatt RB (1966) Studies on the action of a 17a-methyl-B-nortestosterone as an antiandrogen. Steroids 8:297CrossRefGoogle Scholar
  128. Marsden J, Shuster S (1983) Cyclic cyproterone-ethinyloestradiol for acne (letter). Lancet 11:736CrossRefGoogle Scholar
  129. Marsden JR, Shuster S, Lyons F (1983) Is cyclic low dose cyproterone acetate and ethinyloes-tradiol effective in acne? (letter). Lancet 11:215CrossRefGoogle Scholar
  130. Masahashi T, Wu MC, Ohsawa M, Asai M, Ichikawa Y, Hanai K, Kikkawa H, Mizutani S (1986) Spironolactone therapy for hyperandrogenic anovulatory women. Clinical and endocrinological study. Acta Obstet Gynecol Jpn 38:95Google Scholar
  131. Mauvais-Jarvis P, Decourt P (1964) L’inhibition ovraienne thérapeutique par les progestatifs de synthèse. Semin Hôp Paris 40:2659Google Scholar
  132. Menard RH, Stripp B, Gilette JR (1974) Spironolactone and testicular cytochrome P-450: decreased testicular formation in several species and changes in hepatic drug metabolism. Endocrinology 94:1628PubMedCrossRefGoogle Scholar
  133. Messina M, Garione I, Molinatti GM(1970) Spironolattone ed irsutismo femminile. Osservazioni preliminari. Minerva Endocrinol 1:31Google Scholar
  134. Messina M, Manieri C, Rizzi G (1983 a) A new therapeutic approach to acne: an antiandrogen percutaneous treatment with spironolactone. Curr Ther Res 34:319Google Scholar
  135. Messina M, Manieri C, Biffigandi P, Massucchetti C, Novi RF, Molinatti GM (1983 b) Antian-drogenic properties of spironolactone. Clinical trial in the management of female hirsutism. J Endocrinol Invest 6:23PubMedGoogle Scholar
  136. Michel B, Sultan C, Meynadier J (1983) Echec du traitement de l’hirsutisme idiopathique parla Cimetidine. Ann Dermatol Venereol 110:155PubMedGoogle Scholar
  137. Milewicz A, Silber D, Kirschner MA (1983) Therapeutic effects of spironolactone in polycystic ovary syndrome. Obstet Gynecol 61:429PubMedGoogle Scholar
  138. Miller JA, Jacobs HS (1986) Treatment of hirsutism and acne with cyproterone acetate. Clinics in Endocrinology and Metabolism 15:373PubMedCrossRefGoogle Scholar
  139. Miller JA, Wojnarowska FT, Dowd PM, Ashton RE, O’Brien TJO, Griffiths WAD, Jacobs HS (1986) Anti-androgen treatment in women with acne: a controlled trial. Br J Dermatol 114:705PubMedCrossRefGoogle Scholar
  140. Molinatti GM, Messina M, Manieri C, Massucchetti C, Biffignandi P (1983) Current approaches to the treatment of virilizing syndromes. In: Molinatti GM, Martini L, James VHT (eds) Androgenisation in women. Raven, New York, p 179Google Scholar
  141. Moltz L, Kaiser E (1984) Mittelhochdosierte orale Cyproteronacetat-Therapie bei Frauen mit mittelgradig ausgeprägten Androgenisierungserscheinungen. Ergebnisse aus einer multizentrischen Doppelblind-Studie. Geburtshilfe Frauenhkd 44:47CrossRefGoogle Scholar
  142. Moltz L, Meckies J, Hammerstein J (1979) Die kontrazeptive Betreuung androgenisierter Frauen mit einem niedrigdosierten cyproteronacetathaltigen Einphasenpräparat. Dtsch Med Wochenschr 104:1376PubMedCrossRefGoogle Scholar
  143. Moltz L, Fuchs P, Bidlingmeier F, Haase F, Römmler A, Schwartz U, Hammerstein J, Oelkers W (1980) Effects of norethindrone acetate, medroxyprogesterone acetate, and cyproterone acetate on pituitary-adrenal-ovarian function in women. In: 6th International Congress of Endocrinology (Program and abstracts). Melbourne, p 630Google Scholar
  144. Moltz L, Schwartz U, Hammerstein J (1982) Management of cutaneous virilism with cyproterone acetate. In: Jeffcoate SL (eds) Androgens and anti-androgen therapy. Wiley, Chichester, p 113Google Scholar
  145. Moltz L, Haase F, Schwartz U, Hammerstein J (1983) Die Behandlung androgenisierter Frauenmit intramuskulär applizierbarem Cyproteronacetat. Geburtshilfe Frauenhkd 43:281CrossRefGoogle Scholar
  146. Moltz L, Schwartz U, Sörensen R, Pickartz H, Hammerstein J (1984) Ovarian and adrenal vein steroids in patients with nonneoplastic hyperandrogenism: selective catherization findings. Fertil Steril 42:69PubMedGoogle Scholar
  147. Mortimer CH, Rushton H, James KC (1984) Effective medical treatment for common baldness in women. Clin Exp Dermatol 9:342PubMedCrossRefGoogle Scholar
  148. Mosonyi L, Halmy L, Zöld M, Bönsze M, Feher T (1974) Erfahrungen in der Behandlung des Hirsutismus mit antiandrogenen Mitteln. Zbb Gynäkol 96:583Google Scholar
  149. Mowszowicz I, Wright F, Vincens M, Rigaud C, Nahoul K, Mavier P, Guillemant S, Kuttenn F, Mauvais-Jarvis P (1984) Androgen metabolism in hirsute patients treated with cyproterone acetate. J Steroid Biochem 20:757PubMedCrossRefGoogle Scholar
  150. Mühlendahl KE, Weber B, Müller-Hess R, Korth-Schütz S, Helge H (1977) Nebennierenrinden-insuffizienz by Cyproteronacetat-Behandlung. Dtsch Med Wochenschr 102:1074CrossRefGoogle Scholar
  151. Nagel R, Kolb K-H, Kroemer C, Maksimovic P, Laudahn G (1973) Verteilungsstudien und pharmakokinetische Parameter nach i.m.-Gabe von Gestonoron-capronat (Depotstat) und Cyproteronacetat (Androcur) beim Menschen. Verh Dtsch Ges Urol 24:133Google Scholar
  152. Nardi M, De Aloysio D, De Busacchi P, Flamigni C (1975) Cyproterone acetate — ethinylestradiol treatment of hirsutism, acne, seborrhea and alopecia. Acta Eur Fertil 6:152Google Scholar
  153. Nelson RM, Rakoff AE (1970) Hirsutism and acne treated by an androgen antagonist. Obstet Gynecol 36:748PubMedGoogle Scholar
  154. Nielsen DR, Larsen J, Pedersen IM, Starup J (1985) Hirsutisme behandlet med Cyproteronacetatog etinylostradiol. Ugeskr Laeger 147:2589PubMedGoogle Scholar
  155. Nielson PG (1982) Treatment of moderate idiopathic hirsutism with a cream containing canrenone (an antiandrogen). Dermatologica 165:636Google Scholar
  156. Nigam S, Mantell K, Droste-Vehn M, Daniel S, Hammerstein J (1982) Determination of cyproterone acetate and its hydroxylated metabolite in plasma of hirsute patients by high performance liquid chromatography (Poster presentation). In: Sixth international congress on hormonal steroids, Jerusalem, 5–10 Sept 1982Google Scholar
  157. Ober KP, Hennessy JF (1978) Spironolactone therapy for hirsutism in a hyperandrogenic woman. Ann Intern Med 89:643PubMedGoogle Scholar
  158. Pasquali R, Fabbri R, Venturoli S, Paradisi R, Antenucci D, Melchionda N (1986) Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and inuslin resistance in obese patients with polycystic ovaries. Am J Obstet Gynecol 154:139PubMedGoogle Scholar
  159. Peereboom-Wynia JD, Beek CH (1977) The influence of cyproteron-acetate orally on the hair root status in women with idiopathic hirsutism. Arch Dermatol Res 260:137PubMedCrossRefGoogle Scholar
  160. Peereboom-Wynia JDR, Boekhorst JC (1980) Effect of cyproterone acetate orally on hair density and diameter and endocrine factors in women with idiopathic hirsutism. Dermatologica 160:7PubMedCrossRefGoogle Scholar
  161. Perloff WH, Channick BJ, Suplick B, Carrington ER (1958) Clinical management of idiopathic hirsutism (adrenal virilism). JAMA 167:2041CrossRefGoogle Scholar
  162. Pfaffenrath V, Meiers HG, Schmidt-Eimendorff H, Jost B (1975) Trichometrische Erfolgsbeurteilung der Antiandrogentherapie des Hirsutismus. Aktuel Dermatol 1:37Google Scholar
  163. Pittaway DE, Maxson WS, Wentz AC (1985) Spironolactone in combination drug therapy for unresponsive hirsutism. Fertil Steril 43:878PubMedGoogle Scholar
  164. Plehwe WE, Maitland JE, Williams PF, Shearman RP, Turtle JR (1985) Familial hyperinsulinemia complicated by estreme insulin resistance during pregnancy: a probable postreceptor defect. J Clin Endocrinol Metab 61:68PubMedCrossRefGoogle Scholar
  165. Poran J, Guber A, Schindler D, Shachor Y (1986) Pulmonary embolism after short-term treatment of acne vulgaris with ovulation suppressor agents. Med J Aust 145:345PubMedGoogle Scholar
  166. Rabe T, Mossier K, Kiesel L, Runnebaum B (1986) Spironolactonbzw. Cyproteron-Behandlung von Patientinnen mit Androgenisierung. Ber Gynäkol Geburtsh 122:796Google Scholar
  167. Raspe G (ed) (1972) Schering Symposium über Sexualdeviationen und ihre medikamentöse Behandlung. Life science monographs 2. Pergamon, OxfordGoogle Scholar
  168. Rifka SM, Pita JC, Vigersky RA, Wilson YA, Loriaux DL (1978) Interactions of digitalis and spironolactone with human sex steroid receptors. J Clin Endocrinol Metab 46:338PubMedCrossRefGoogle Scholar
  169. Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH (1977) Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 87:398PubMedGoogle Scholar
  170. Rubens R (1984) Androgen levels during cyproterone acetate and ethinyl oestradiol treatment of hirsutism. Clin Endocrinol (Oxf) 20:313CrossRefGoogle Scholar
  171. Rubens R, Vermeulen A (1985) Antiandrogens in the treatment of hirsutism. J Steroid Biochem 23 (Suppl) 23:33SCrossRefGoogle Scholar
  172. Salva P, Morer F, Ordonez J, Rodriguez J (1983) Treatment of idiopathic hirsute women with two combinations of cyproterone acetate. Int J Clin Pharmacol Res 3:129PubMedGoogle Scholar
  173. Salvador J, Barberia JJ, Marti J, Forga L, Saavedra J, Moncada E (1985) Time dependency and reversibility of the effects of exclusive cyproterone acetate therapy in pituitary adrenal function in hirsute women. Acta Endocrinol (Copenh) 110:164Google Scholar
  174. Scheuer A, Hagen C, Loeck M, Müller R (1980) Der Einfluß von Cyproteronacetat auf die Nebennieren- und Gonadenfunktion. Med Welt 31:1557PubMedGoogle Scholar
  175. Schindler AE, Mangold K, Friedrich E, Keller E, Goeser R (1978) Therapy of androgenetic sympatomatology with cyproterone acetate and ethinyl estradiol. Arch Gynecol 225:103Google Scholar
  176. Schleusener A, Nishino Y, Albring M, Neumann F, Beier S (1980) Endocrine profile of a cyproterone acetae (CPA) metabolite and its potential clinical use. Acta Endocrinol (Copenh) 94 (Suppl 234): 106Google Scholar
  177. Schmidt JB, Spona J (1986) Topische Cimetidinbehandlung bei Akne. Z Hautkr 61:1065PubMedGoogle Scholar
  178. Schmidt-Eimendorff H, Steyer M (1977) Klinische Erfahrungen mit einem niedrig dosierten Antiandrogen (Cyproteronazetat) und Äthinylöstradiol bei Frauen mit Virilisierungserscheinungen. Geburtshilfe Frauenhdk 37:297Google Scholar
  179. Schmidt-Eimendorff H, Kaiser E, Bauchwitz MA (1967) Der Einfluß eines Antiandrogens auf die Gonadotropinausscheidung, das Endometrium und den Vaginalsmear bei Frauen mit Hirsutismus. Ach Gynec 204:133Google Scholar
  180. Seed M, Godsland IF, Wynn V, Jacobs HS (1984) The effects of cyproterone acetate and ethinyloestradiol on carbohydrate metabolism. Clin Endocrinol (Oxf) 21:689CrossRefGoogle Scholar
  181. Serafîni P, Lobo RA (1985) The effects of spironolactone on adrenal steroidogenesis in hirsute women. Fertil Steril 44:595PubMedGoogle Scholar
  182. Serafîni PC, Catalino J, Lobo RA (1985) The effect of spirinolactone on genital skin 5a-reductase activity. J Steroid Biochem 23:191PubMedCrossRefGoogle Scholar
  183. Shapiro G, Evron S (1980) A novel use of spironolactone: treatment of hirsutism. J Clin Endocrinol Metab 51:429PubMedCrossRefGoogle Scholar
  184. Shuster S (1985) Alopecia and hirsutism: a personal view. Prescr J 25:12Google Scholar
  185. Silvestrini F (1977) Use of antiandrogens in female endocrinology. In: Martini L, Motta M (eds) Androgens and antiandrogens. Raven, New York, p 361Google Scholar
  186. Smals AGH, Kloppenborg PWC, Goverde HJM, Benraad TJ (1978) The effect of cyproterone acetate on the pituitary-adrenal axis in hirsute women. Acta Endocrinol (Copenh) 87:352Google Scholar
  187. Spandri P, Gangemi M, Nardelli GB, Meneghetti G, Grandesso R, De Salvia D, Ambrosio GB, Predebon O (1984) Testosterone, 17 KS, 17ßE2, FSH-LH-variations and hirsutism. Clin Exp Obstet Gynecol 11:49PubMedGoogle Scholar
  188. Speck U, Jentsch D, Kühne G, Schulze PE, Wendt H (1976 a) Bioverfügbarkeit und Pharmakokinetik von 14 C-Cyproteronacetat nach Applikation als 50-mg-Tablette. Arzneimittelforschung 26:1717PubMedGoogle Scholar
  189. Speck U, Wendt H, Schulze PE, Jentsch D (1976 b) Bio-availability and pharmacokinetics of cyproterone acetate-14C and ethinyloestradiol-3H after oral administration as a coated tablet (SH 209 AB). Contraception 14:151PubMedCrossRefGoogle Scholar
  190. Spona J, Huber J, Schmidt J (1986) Inhibierung der Ovulation mit 35 Mikrogramm Äthinyl-östradiol und 2 mg Cyproteronazetat (Diane-35). Geburtshilfe Frauenheilkd 46:435PubMedCrossRefGoogle Scholar
  191. Stoppeiii E, Reiner E, Hümpel M (1980) Transfer of cyproterone acetate to the milk of lactating women. Contraception 22:485CrossRefGoogle Scholar
  192. Strauss JS, Pochi PE, Sarada IR, Wotiz HH (1969) Effect of oral and topical 17a methyl-B-nor-testosterone on sebum production and plasma testosterone. J Invest Dermatol 52:95PubMedGoogle Scholar
  193. Strauss JS, Pochi PE (1970) Assay of anti-androgens in man by the sebaceous gland response. Br J Dermatol 82 (Suppl 6):33CrossRefGoogle Scholar
  194. Sultan A, Terraza B, Descomps B, de Paulet AC (1980) Cimetidine competition with androgens for binding to human sex skin fibroblasts androgen receptors. J Steroid Biochem 13:839PubMedCrossRefGoogle Scholar
  195. Sutton TJ (1979) Dermal toxicity and penetration studies following topical application of three histamine H 2-receptor antagonists with a comparison with an H 1-receptor antagonist. Toxicol Appl Pharmacol 50:459PubMedCrossRefGoogle Scholar
  196. Tamm J, Voigt KD, Schönrock M, Ludwig E (1970) The effect of orally administered cyproterone on the sebum production in human subjects. Acta Endocrinol 63:50PubMedGoogle Scholar
  197. Tejero A, Guadalix FJ, Botella, Llusia J (1977) L’action de l’acétate de cyprotérone sur la testo-stérone plasmatique de la femme atteinte d’hirsutisme. J Gynecol Obstet Biol Reprod (Paris) 6:683Google Scholar
  198. Thomas AK, Slobodniuk, R, Taft J, Cooper M, Montalto J, Jerums G (1985) The treatment of hirsutism: experience with cyproterone acetate and spironolactone. Australas J Dermatol 26:19PubMedCrossRefGoogle Scholar
  199. Tremblay RR (1986) Treatment of hirsutism with spironolactone. Clin Endocrinol Metab 15:363PubMedCrossRefGoogle Scholar
  200. Underhill R, Dewhurst J (1979) Further clinical experience in the treatment of hirsutism with cyproterone acetate. Br J Obstet Gynaecol 86:139PubMedCrossRefGoogle Scholar
  201. Valenti G, Vescovi PP, Gerra G, Rastelli G, Butturini U (1985) Activation of PRL secretion by combined treatment with cyproterone acetate and ethinylestradiol. J Endocrinol Invest 8:269PubMedGoogle Scholar
  202. van Wayjen RGA, van den Ende A (1971) Clinical pharmacological investigation of cyproteroneacetate. Gynecol Invest 2:282PubMedCrossRefGoogle Scholar
  203. van Wayjen RGA, van den Ende A (1976) Het anti-androgene steroid cyproterone-acetaat. Klinische farmacologie en toepassing bij hirsutisme en acne. Ned Tijdschr Geneesk 120:189Google Scholar
  204. van Wayjen RGA, van den Ende A (1980) Metabolic effects of cyproterone acetate. In: Hammerstein J, Lachnit-Fixson U, Neumann F, Plewig G (eds) Androgenization in women. Excerpta Medica, Amsterdam, p 247Google Scholar
  205. van Wayjen RGA, van den Ende A (1981) Effect of cyproterone acetate on pituitary-adrenocortical function in man. Acta Endocrinol (Copenh) 96:112Google Scholar
  206. van Wayjen RGA, van den Ende A (1983) Long-term treatment of hirsutism and acne with cyproterone acetate (Abstract 32). In: Internat study group for steroid hormones, 11th meeting, Rome, November 1983.Bulletin, vol 2Google Scholar
  207. Venturoli S, Paradisi R, Saviogotti E, Porcu E, Fabbri R, Orsini LF, Bovicelli L, Flamigni C (1985) Ultrasound study by ovarian and uterine morphology in women with policystic ovary syndrome before, during after treatment with cyproterone acetate and ethinyloestradiol. Arch Gynecol 237:1PubMedCrossRefGoogle Scholar
  208. Vermorken AJM, Goos CMAA, Roelofs HMJ (1980) A method for the evaluation of the local antiandrogenic action of 5a-reductase inhibitors on human skin. Br J Dermatol 102:695PubMedCrossRefGoogle Scholar
  209. Vigersky RA, Mehlmann I, Glass AR, Smith CE (1980) Treatment of hirsute women with Cimetidine. N Engl J Med 303:1042PubMedCrossRefGoogle Scholar
  210. Walton S, Cunliffe WJ, Lookingbill P, Keczkes K (1986) Lack of effect of topical spironolactone on sebum excretion. Br J Dermatol 114:261PubMedCrossRefGoogle Scholar
  211. Wilkins LMR, Lewis RA, Klein R, Rosemberg E (1950) The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia, preliminary report. Bull Johns Hopkins Hosp 86:249PubMedGoogle Scholar
  212. Winkler K (1968) Die Antiandrogene in der Dermatologie. Gravimetrische Fettbestimmungen während Cyproteronanwendung. Arch Klin Exp Dermatol 233:296PubMedCrossRefGoogle Scholar
  213. Winkler K, Schaeffer H (1973) Das Verhalten der Talgsekretion während der Behandlung der Akne mit Cyproteronacetat und Äthinylöstradiol. Arch Dermatol Forsch 247:259PubMedCrossRefGoogle Scholar
  214. Wynn V, Godsland IF, Seed M, Jacobs HS (1986) Paradoxical effects of the anti-androgen cyproterone acetate on lipid and lipoprotein metabolism. Clin Endocrinol (Oxf) 24:183CrossRefGoogle Scholar
  215. Ylöstalo P, Laakso L, Viinikka L, Ylikorkalo O, Vihko R (1981) Cyproterone acetate in the treatment of hirsutism. Acta Obstet Gynecol Scand 60:399PubMedCrossRefGoogle Scholar
  216. Zarate A, Mahesh VB, Greenblatt RB (1966) Effect of an antiandrogen, 17a-methyl-B-nortes-tosterone, on acne and hirsutism. J Clin Endocrinol 26:1394CrossRefGoogle Scholar
  217. Zaun H (1976) Systemische Therapie mit Sexualhormonen in der dermatologischen Praxis. Akt Dermatol 2:33Google Scholar
  218. Zaun H (1983) Some new aspects in the diagnosis and treatment of non-cicatricial alopecias. In: Kukita A, Seiji M (eds) Proceedings of the 16th international congress of dermatology. University of Tokio Press, Tokio, p 113Google Scholar
  219. Zaun H (1984) Indikation und Grenzen der antiandrogenen Therapie. Z Hautkr 59:1090PubMedGoogle Scholar
  220. Zielske F, Leo-Roßberg I, Dreykluft R, Römmler A, Hammerstein J (1971) Treatment of hirsutism and signs of virilism with a reversed sequential administration of cyproterone acetate and ethinyl oestradiol. Clinical and endocrinological aspects. Acta Endocrinol (Copenh) [Suppl] 155:172Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • J. Hammerstein

There are no affiliations available

Personalised recommendations